Cargando…

56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy

INTRODUCTION: The prognosis of chronic inflammatory diseases has been transformed by the use of biologic drugs. However, there is evidence of an increased risk of infection in patients undergoing biotherapy. The objective of our study was to investigate the frequency and the severity of infections i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiba, Ben Ayed, Sarra, Ben Yacoub, Manel, Boudokhane, Rym, Bourguiba, Zeineb, Teyeb, Mariem, Ayari, Taieb, Jomni, Imen, Abdelaali, Syrine, Belakhal, Hedi, Dougui Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539024/
http://dx.doi.org/10.1093/rheumatology/keac496.052
_version_ 1784803423491719168
author Hiba, Ben Ayed
Sarra, Ben Yacoub
Manel, Boudokhane
Rym, Bourguiba
Zeineb, Teyeb
Mariem, Ayari
Taieb, Jomni
Imen, Abdelaali
Syrine, Belakhal
Hedi, Dougui Mohamed
author_facet Hiba, Ben Ayed
Sarra, Ben Yacoub
Manel, Boudokhane
Rym, Bourguiba
Zeineb, Teyeb
Mariem, Ayari
Taieb, Jomni
Imen, Abdelaali
Syrine, Belakhal
Hedi, Dougui Mohamed
author_sort Hiba, Ben Ayed
collection PubMed
description INTRODUCTION: The prognosis of chronic inflammatory diseases has been transformed by the use of biologic drugs. However, there is evidence of an increased risk of infection in patients undergoing biotherapy. The objective of our study was to investigate the frequency and the severity of infections in patients on biotherapy. METHODS: We conducted a retrospective descriptive study including all patients followed in the internal medicine department of the ISF hospital and treated with biotherapy over a period of 14 years [2009–2022]. RESULTS: We identified 50 patients treated with biologic therapy among 76 patients. The patient’s mean age was 48 years± 12.5 [23–76] and male to female ratio (M: F) was 1 :6. The mean age at initiation of biotherapy was 41.3 ± 11.6 [17–68] years. The molecules used were TNFα inhibitors in 82% of cases, rituximab in 14% of cases and tocilizumab in 4%. Infectious complications were identified in 20 patients. Infections occurred after a mean duration of 12 months [0.5–36] after the initiation of biotherapy. They affected the skin in nine cases, the bronchopulmonary tract in seven cases, the central nervous system in four cases, the gastrointestinal tract in three cases, and the upper respiratory tract in two cases. The infection was bacterial in 16 cases (64%), viral in five cases (20%) and fungal in four cases (16%). We report five cases of tuberculosis (TB), including four cases of pulmonary TB and one case of neuro-meningeal TB. The infection was severe, requiring hospitalization in only eight cases (32%). The median duration of hospitalization was 12 days [2–58]. The infectious episode led to temporary interruption of biotherapy in six cases and definitive interruption in two cases. No deaths were noted. CONCLUSION: Our study confirms the increased susceptibility to infections in patients treated with biologics. These infections, often bacterial, are in the majority of cases benign. However, tuberculosis remains frequent.
format Online
Article
Text
id pubmed-9539024
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95390242022-10-07 56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy Hiba, Ben Ayed Sarra, Ben Yacoub Manel, Boudokhane Rym, Bourguiba Zeineb, Teyeb Mariem, Ayari Taieb, Jomni Imen, Abdelaali Syrine, Belakhal Hedi, Dougui Mohamed Rheumatology (Oxford) E Posters INTRODUCTION: The prognosis of chronic inflammatory diseases has been transformed by the use of biologic drugs. However, there is evidence of an increased risk of infection in patients undergoing biotherapy. The objective of our study was to investigate the frequency and the severity of infections in patients on biotherapy. METHODS: We conducted a retrospective descriptive study including all patients followed in the internal medicine department of the ISF hospital and treated with biotherapy over a period of 14 years [2009–2022]. RESULTS: We identified 50 patients treated with biologic therapy among 76 patients. The patient’s mean age was 48 years± 12.5 [23–76] and male to female ratio (M: F) was 1 :6. The mean age at initiation of biotherapy was 41.3 ± 11.6 [17–68] years. The molecules used were TNFα inhibitors in 82% of cases, rituximab in 14% of cases and tocilizumab in 4%. Infectious complications were identified in 20 patients. Infections occurred after a mean duration of 12 months [0.5–36] after the initiation of biotherapy. They affected the skin in nine cases, the bronchopulmonary tract in seven cases, the central nervous system in four cases, the gastrointestinal tract in three cases, and the upper respiratory tract in two cases. The infection was bacterial in 16 cases (64%), viral in five cases (20%) and fungal in four cases (16%). We report five cases of tuberculosis (TB), including four cases of pulmonary TB and one case of neuro-meningeal TB. The infection was severe, requiring hospitalization in only eight cases (32%). The median duration of hospitalization was 12 days [2–58]. The infectious episode led to temporary interruption of biotherapy in six cases and definitive interruption in two cases. No deaths were noted. CONCLUSION: Our study confirms the increased susceptibility to infections in patients treated with biologics. These infections, often bacterial, are in the majority of cases benign. However, tuberculosis remains frequent. Oxford University Press 2022-10-07 /pmc/articles/PMC9539024/ http://dx.doi.org/10.1093/rheumatology/keac496.052 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle E Posters
Hiba, Ben Ayed
Sarra, Ben Yacoub
Manel, Boudokhane
Rym, Bourguiba
Zeineb, Teyeb
Mariem, Ayari
Taieb, Jomni
Imen, Abdelaali
Syrine, Belakhal
Hedi, Dougui Mohamed
56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy
title 56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy
title_full 56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy
title_fullStr 56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy
title_full_unstemmed 56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy
title_short 56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy
title_sort 56 prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy
topic E Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539024/
http://dx.doi.org/10.1093/rheumatology/keac496.052
work_keys_str_mv AT hibabenayed 56prevalenceandseverityofinfectionsinpatientswithsystemicautoimmunediseasesonbiotherapy
AT sarrabenyacoub 56prevalenceandseverityofinfectionsinpatientswithsystemicautoimmunediseasesonbiotherapy
AT manelboudokhane 56prevalenceandseverityofinfectionsinpatientswithsystemicautoimmunediseasesonbiotherapy
AT rymbourguiba 56prevalenceandseverityofinfectionsinpatientswithsystemicautoimmunediseasesonbiotherapy
AT zeinebteyeb 56prevalenceandseverityofinfectionsinpatientswithsystemicautoimmunediseasesonbiotherapy
AT mariemayari 56prevalenceandseverityofinfectionsinpatientswithsystemicautoimmunediseasesonbiotherapy
AT taiebjomni 56prevalenceandseverityofinfectionsinpatientswithsystemicautoimmunediseasesonbiotherapy
AT imenabdelaali 56prevalenceandseverityofinfectionsinpatientswithsystemicautoimmunediseasesonbiotherapy
AT syrinebelakhal 56prevalenceandseverityofinfectionsinpatientswithsystemicautoimmunediseasesonbiotherapy
AT hedidouguimohamed 56prevalenceandseverityofinfectionsinpatientswithsystemicautoimmunediseasesonbiotherapy